- Select a blog category
This week Deloitte launched its report, 2018 Global health care outlook: The evolution of smart health care - which looks at the challenges health care will be facing in 2018 and the strategies that can be utilised to alleviate the pressures facing the sector globally. This week’s blog highlights some of the key findings from the report and their implications for the UK.
This week, we published our eighth annual report on Measuring the return from pharmaceutical innovation. Our report tracks the annual return on investment that the 12 leading biopharma companies (by 2009 R&D spend) might expect to achieve from their late-stage pipelines, as well as tracking the performance of an extension cohort of four mid-to-large cap biopharma companies for the third consecutive year. This week's blog by Matthew Thaxter, an analyst at the centre, gives his take on the findings from this year’s report.
Stories give people permission to talk – they give staff, patients and their families a voice that touches everyone who listens. Last week we published our report Time to care which highlights the importance of supporting the physical and mental wellbeing of hospital staff in order to ensure a sustainable and effective workforce. This Thursday I attended an inspiring event called ‘The DNA of Care’, a shared learning event hosted by NHS England. The event showcased a series of digital stories developed by Patient Voices and an evaluation of how digital stories are being used to provide a voice to NHS staff as part of their DNA of Care project.1 During the event I was struck by the power of staff stories and how these stories could help tackle some of the challenges identified in our research. I have long been a strong advocate of the power of digital stories. This week’s blog shares some of my insights from this event and why I believe digital stories are not only incredibly impactful and cathartic for the people involved in telling their stories, but can help others understand the amazing courage, resilience and compassion of NHS staff.
Access to high-quality health care is a fundamental human right, for improving the health of both individuals and the population as a whole. Health professionals are the most important asset in any health system and represent a significant investment. While countries differ in how they fund health care, how much they are prepared to pay for services and which services they prioritise, the quality of care is dependent on having the right professionals with the right skills in the right place at the right time. This week we launched our latest report, Time to care: Securing a future for the hospital workforce in Europe. The overarching theme is a universal concern about workforce shortages and the lack of time for hands-on care. Countries across Europe are facing increasing challenges with regard to the growing demands placed on the workforce which raises important questions about the sustainability of current workforce models. Having led the research for this report for the past six months, this week’s blog provides my take on the report’s key findings, the challenges identified and some of the potential solutions to these challenges.
This month we published our report The future awakens: Life sciences and health care predictions 2022, where we discussed the future of medicine and how technologies such as genomics, precision therapies and artificial intelligence (AI) will shape our understanding of our own genetic make-up and ultimately improve patient outcomes. One technology that we didn’t highlight in the report, is nanotechnology, principally because we expect it to take more than five years to become a central part of healthcare. Nanotechnology has been touted as a technology that could revolutionise our world since the late 1950’s. However, scientific and economic barriers means the commercialisation of products incorporating nanotechnology in life sciences has been limited. Despite this lack of commercialisation, a new wave of nanotech-based therapies are on the horizon. This week’s blog by Amen Sanghera, an analyst here at the Centre who studied the topic at university, looks at the potential benefits and current limitations of nanotechnology in the life sciences industry.
In 2014 we launched our first predictions report - Healthcare and life sciences predictions 2020: A bold future? It provided an intentionally positive and provocative view of what the world might look like in 2020. Since then the pace and scale of innovation has meant that some of these predictions are already a reality, while some are still some way off; yet others may never happen. Moreover, in the intervening years, the life sciences and health care industries are waking up to the fact that new science, automation and robotics will have a significant impact on the future of work. Last week we launched our newest predictions report - ‘The future awakens: Life Sciences and health care predictions 2022’. This week’s blog provides an overview of our six predictions and an example of the evidence today that enables us to say with some confidence what tomorrow might look like.
Discussing a long standing health concern is difficult for anyone. However, men have a more difficult time in firstly realising they may have a health issue and secondly discussing it in an open way which would benefit their treatment. Crucial to improving the long term health of men is increasing public education on often understated issues in men’s health, and fostering an environment in which health issues can be discussed openly and without ridicule. This week’s blog, by Amen Sanghera, one of two analysts here at the centre, looks into the issues men have regarding discussing health concerns and the work charities, such as Movember, do to raise awareness for key issues in men’s health.
Just over a week ago, the media was awash with news about mental health, the focus this time was on its impact on businesses of all sizes in the UK. The interest was fanned by the publication of the independent review into workplace mental health, commissioned by the Prime Minister in January 2017. Thriving at Work: The Stephenson/ Farmer review of mental health, set out what employers can do to better support all employees, including those with mental health problems to remain in and thrive through work.1 In the light of this important issue, this week we’re featuring a mid-week blog, by Liz Hampson and Ushma Soneji - who supported the independent review over the past six months. Their specific task was to develop the case for investment that underpins the review’s recommendations. Their report, Mental health and employers: The case for investment, provides detailed insight into the cost to employers of failing to address and support mental wellbeing in the workplace.2 Deloitte’s report was published alongside the review, and attracted wide media attention.
This week, Deloitte and the think tank Reform published The State of the State 2017-18, our annual report on the UK’s public sector, based on fresh research that includes a citizen survey of 1,000 members of the public and in-depth interviews with 45 public sector leaders, including leaders from both health and social care. Having read The State of the State from a healthcare perspective, three issues caught my attention relating to data, austerity and demand.
Computer and smart phone applications are pervasive across the world and cover almost every conceivable facet of a peoples lifestyle choices. As of March 2017, the two largest app stores had a collective library of apps totalling 5 billion.i However, as demonstrated by our report, ‘Pharma and the connected patient: How digital technology is enabling patient centricity’, the uptake of applications produced by Life Science companies remains low. This week’s blog is by David Rosner, a principle in the firm’s US practice, and it was recently featured on the US Centre for Health Solutions site.ii David references our report and explores some of the reasons for the low uptake of applications by Life Sciences companies.
State of the smart: Mobile consumer patterns and their implications for life sciences and health care
Earlier this month saw the launch of the seventh edition of Deloitte’s “Mobile Consumer Survey: The UK Cut”. The survey explores the state of the current mobile landscape and how it is likely to change over the next five years. It contains data from 4,150 respondents in the UK aged 16-75 and is a cut of the global survey that provides unique insight into the mobile usage behaviour of nearly 53,000 respondents across 33 countries. In this week’s blog, I look at some of the data from the UK Cut and explore what it means for consumers in the health care and life sciences industries.